Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma

@inproceedings{Das2014StevensJS,
  title={Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma},
  author={Anupam Das and Amrita Sil and Vivek Mishra and Nilay Kanti Das},
  booktitle={Indian journal of pharmacology},
  year={2014}
}
Thalidomide developed in 1954 for morning sickness had proven to be a teratogen and hence was withdrawn from market. Resurgence of thalidomide began as an immunomodulator when it was shown to be effective in the management of multiple myeloma and many conditions like erythema nodosum leprosum, graft versus host disease, recurrent aphthous ulcers etc. We… CONTINUE READING